Cell line · CVCL_3114
Papers43
1 to 20 of 43
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| piR-823 and piR-20326 Differentially Regulate Stemness Programs in Ovarian Cancer Stem-like Cells. | Int J Mol Sci | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Patient-derived model capturing hypoxia and extracellular matrix remodelling of immunologically cold high-grade serous tumours. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| DNA Methyltransferase Inhibition Prevents Platinum-Induced Ovarian Cancer Stem Cell Enrichment. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Steroid-Metabolizing Enzymes with 15β-Substituted Estrone Analogues: Dual Discovery of AKR1C2/17β-HSD1 Inhibitors and a Fluorescent 17β-HSD1 Ligand. | Cancers (Basel) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Tumor-Infiltrating Nociceptor Neurons in Ovarian Cancer Treatment Resistance. | Adv Biol (Weinh) | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Repurposing of ivacaftor shows potential to treat ROR1 expressing high-grade serous ovarian cancer. | Ther Adv Med Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Dynamic and Ongoing De Novo L1 Retrotransposition Contributes to Genome Plasticity and Intrapatient Heterogeneity in Ovarian Cancer. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| PLK1 or WEE1 inhibition targets homologous recombination repair proficiency in BRCA1/2 wild-type high-grade serous ovarian cancer. | Cell Death Dis | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting SUMOylation in ovarian cancer: Sensitivity, resistance, and the role of MYC. | iScience | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer. | Mol Oncol | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Aged and BRCA-Mutated Stromal Cells Drive Epithelial Cell Transformation. | Cancer Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Tumor Suppressors Condition Differential Responses to the Selective CDK2 Inhibitor BLU-222. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Targeting Ovarian Cancer Stem Cells by Dual Inhibition of the Long Noncoding RNA HOTAIR and Lysine Methyltransferase EZH2. | Mol Cancer Ther | 2024 | Its Methods give the RRID and name the line | PubMed | |
| WNT4 Regulates Cellular Metabolism via Intracellular Activity at the Mitochondria in Breast and Gynecologic Cancers. | Cancer Res Commun | 2024 | Its Methods give the RRID and name the line | PubMed | |
| DNA damage induces nuclear envelope rupture through ATR-mediated phosphorylation of lamin A/C. | Mol Cell | 2023 | Its Methods give the RRID and name the line | PubMed | |
| A novel cell line panel reveals non-genetic mediators of platinum resistance and phenotypic diversity in high grade serous ovarian cancer. | Gynecol Oncol | 2022 | Cellosaurus cites it | PubMed | |
| KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. | Cancer Immunol Res | 2022 | Its Methods give the RRID and name the line | PubMed | |
| Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells. | Front Oncol | 2021 | Its Methods give the RRID and name the line | PubMed | |
| TGF-β1 potentiates Vγ9Vδ2 T cell adoptive immunotherapy of cancer. | Cell Rep Med | 2021 | Its Methods give the RRID and name the line | PubMed | |
| The SETDB1-TRIM28 Complex Suppresses Antitumor Immunity. | Cancer Immunol Res | 2021 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3114/papers